BridgeBio Pharma, Inc.
NasdaqGS:BBIO
$ 28.94
$-0.04 (-0.14%)
$ 28.94
$-0.04 (-0.14%)
End-of-day quote: 03/11/2024

BridgeBio Pharma financials at a glance

The revenue of BridgeBio Pharma is reported as 0.0093 billion Dollars in the fiscal year 2023. The earnings were -3.9 Dollars per share in 2023, which was 5.41 lower than 2022. And about -0.47998 billion Dollars are reported as free cash flow in the financials of BridgeBio Pharma 2023. No dividends were paid to the shareholders of the BridgeBio Pharma stock NasdaqGS:BBIO in the financial year 2023.

$9.30M
Revenue
$-3.90
Earnings Per Share
73.71%
Gross Margin %
$-,459.67M
Free Cash Flow
Revenue
9.30
Earnings Per Share
-3.90
Gross Margin %
73.71
Free Cash Flow
-,459.67

Financials

Year Year TTM 2023 2022 2021 2020 2019
Rev. Revenue N/A $9.30M $77.65M $69.72M $8.25M $40.56M
GM % Gross Margin % 73.54% 73.71% 95.58% 95.53% 100.00% 93.84%
OM Operating Margin 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Earnings Per Share $-3.91 $-3.90 $-3.70 $-3.90 $-3.80 $-2.48
Div. Dividends N/A $0.00 $0.00 $0.00 $0.00 $0.00
PR % Payout Ratio % 0 -0.00% -0.00% -0.00% -0.00% -0.00%
Sha. Shares N/AM 175.83M 151.37M 147.61M 146.54M 123.77M
OCF Operating Cash Flow N/A $-,478.67M $-,419.49M $-,497.93M $-,399.71M $-,253.59M
FCF Free Cash Flow N/A $-,459.67M $-,424.32M $-,511.18M $-,407.23M $-,256.23M
FCFS Free Cash Flow Per Share $-3.18 $-3.25 $-2.89 $-3.78 $-3.45 $-2.46